Amplicon-Based Semiconductor Sequencing in Biomarker Cancer Testing

Doing More with Smaller Tissue Samples

Traditional next-generation sequencing (NGS) methods, such as hybrid capture, often require large tissue samples, posing challenges in clinical scenarios, particularly oncology, where obtaining sufficient material can be difficult. These limitations can lead to diagnostic delays and suboptimal treatment decisions that adversely affect patients and increase costs for healthcare institutions.

In this webinar, explore the advantages of amplicon-based semiconductor sequencing, a technology that allows for the successful sequencing of smaller tissue samples. Learn how this approach can overcome the constraints of traditional methods, improve diagnostic accuracy, expedite treatment decisions, and enhance overall care. Gain insights into the practical implementation of amplicon-based semiconductor sequencing and discover how it can streamline clinical workflows and deliver better patient outcomes.

Learning Objectives

This webinar will help you:

• Examine the constraints of traditional sequencing techniques such as hybrid capture
• Clarify the mechanisms and advantages of amplicon-based semiconductor sequencing, including its principles, methodologies, and more
• Evaluate the practical applications of amplicon-based semiconductor sequencing in clinical settings and its impact on clinical and research outcomes
• Manage the integration of amplicon-based semiconductor sequencing into existing clinical workflows and research protocols

Watch On Demand   Download Slides (PDF, 1.1 MB)

Fisher Healthcare is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.™ Program. One P.A.C.E.™ credit-hour will be provided for this complimentary basic level program.

Allison M. Cushman-Vokoun, MD, PhD, FCAP, Director of the Division of Diagnostic Molecular Pathology and Human Genetics and Medical Director of the Molecular Diagnostics and Personalized Medicine Laboratory at the University of Nebraska Medical Center

As a professor at the University of Nebraska Medical Center, Dr. Cushman-Vokoun oversees molecular biomarker test development in molecular oncology, with expertise in next-generation sequencing in solid tumor and hematopoietic malignancies. She serves as an expert on many national pathology society committees and is highly involved in molecular pathology education at the local and national levels.